Clinical trial
A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study to Assess the Safety, Tolerability and Efficacy of Terpenes-enriched Cannabis Oil T1/C28, Administered to Pediatric Subjects With Autism Spectrum Disorder (ASD)
NCT07199218 is registered in ClinicalTrials.gov with Bazelet Nehushtan LtD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study to Assess the Safety, Tolerability and Efficacy of Terpenes-enriched Cannabis Oil T1/C28, Administered to Pediatric Subjects With Autism Spectrum Disorder (ASD)
- Lead sponsor
- Bazelet Nehushtan LtD.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 5, 2025
- Completion date
- March 3, 2028
- Enrollment
- 78 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
autism, autism spectrum disorder